Mesh Bio

SINGAPORE. East Ventures, a capital venture that has been quite generous to Indonesian start-ups, is reportedly leading series A funding worth USD 3.5 million for Mesh Bio.

Mesh Bio is a health-tech start-up from Singapore, with the focus on technology development for chronic illness management through predictive analysis. This funding is well received by Mesh Bio after securing the license from Health Sciences Authority of Singapore to market HealthVector Diabetes SaMD (Software Medical Device) in several hospitals and clinics.

Said funding also involves participation of several well-known investors, such as Elev 8 and Seed Capitals. In addition, there is also additional funding from existing investors.

Willson Cuaca, Co-Founder and Managing Partner of East Ventures, said that this funding will support Mesh Bio's innovation to generate a more personal and preventive healthcare service. "We expect further collaboration in transforming healthcare services in South East Asia and surrounding region," he explained to IDNFinancials.

Meanwhile, Andrew Wu, Co-Founder and CEO of Mesh Bio, said that this funding will expand the scope of service and solution initiated by Mesh Bio to Hong Kong and South East Asia, including Indonesia and the Philippines. (KR/ZH)